NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
Hybio Pharmaceutical Co. Ltd (SHE: 300199)
300199 Technical Analysis
4
As on 20th Dec 2024 300199 STOCK Price closed @ 15.72 and we RECOMMEND Buy for LONG-TERM with Stoploss of 12.51 & Strong Buy for SHORT-TERM with Stoploss of 10.12 we also expect STOCK to react on Following IMPORTANT LEVELS. |
300199STOCK Price
Open | 14.10 | Change | Price | % |
High | 15.95 | 1 Day | 1.71 | 12.21 |
Low | 13.78 | 1 Week | 2.49 | 18.82 |
Close | 15.72 | 1 Month | 3.88 | 32.77 |
Volume | 99244525 | 1 Year | 4.49 | 39.98 |
52 Week High 19.38 | 52 Week Low 8.77 |
SHE China Most Active Stocks
002131 | 4.21 | 8.23% |
002195 | 4.99 | 1.22% |
002607 | 3.93 | -4.15% |
000100 | 5.07 | -1.93% |
002354 | 7.24 | -9.95% |
000564 | 3.61 | 0.00% |
002239 | 3.40 | -7.61% |
300059 | 26.11 | 1.01% |
002122 | 5.51 | 9.98% |
000981 | 2.51 | 0.40% |
SHE China Top Gainers Stocks
SHE China Top Losers Stocks
300199 Daily Charts |
300199 Intraday Charts |
Whats New @ Bazaartrend |
300199 Free Analysis |
|
300199 Important Levels Intraday
RESISTANCE | 19.90 |
RESISTANCE | 18.56 |
RESISTANCE | 17.73 |
RESISTANCE | 16.90 |
SUPPORT | 14.54 |
SUPPORT | 13.71 |
SUPPORT | 12.88 |
SUPPORT | 11.54 |
300199 Forecast December 2024
4th UP Forecast | 21.75 |
3rd UP Forecast | 19.82 |
2nd UP Forecast | 18.62 |
1st UP Forecast | 17.43 |
1st DOWN Forecast | 14.01 |
2nd DOWN Forecast | 12.82 |
3rd DOWN Forecast | 11.62 |
4th DOWN Forecast | 9.69 |
300199 Weekly Forecast
4th UP Forecast | 17.51 |
3rd UP Forecast | 16.94 |
2nd UP Forecast | 16.58 |
1st UP Forecast | 16.23 |
1st DOWN Forecast | 15.21 |
2nd DOWN Forecast | 14.86 |
3rd DOWN Forecast | 14.50 |
4th DOWN Forecast | 13.93 |
300199 Forecast2024
4th UP Forecast | 39.27 |
3rd UP Forecast | 31.72 |
2nd UP Forecast | 27.05 |
1st UP Forecast | 22.38 |
1st DOWN Forecast | 9.06 |
2nd DOWN Forecast | 4.39 |
3rd DOWN Forecast | -0.28 |
4th DOWN Forecast | -7.83 |
Hybio Pharmaceutical Co. Ltd ( SHE China Symbol : 300199 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
300199 Other Details
Segment | EQ | |
Market Capital | 4456265216.00 | |
Sector | Healthcare | |
Industry | Drug Manufacturers-Specialty & Generic | |
Offical website | > echo $website ; ?> |
300199 Address
300199 Latest News
300199 Business Profile
Hybio Pharmaceutical Co., Ltd., a peptide pharmaceutical company, engages in the research and development, manufacture, and sale of polypeptide drugs in the People's Republic of China and internationally. Its peptide finished dosage products include digestive system agents, immune modulators, PTH and Ca metabolic modulators, hormone and endocrine modulators, FD for circulatory and blood systems, antiviral agents, and hemostatic products. The company also provides custom and GMP peptides; and a range of peptide APIs. Hybio Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China. Address: No. 37, Keji C. 2nd, Shenzhen, China, 518057
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service